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the MRL, as well as measurable paramagnetic changes 
observed using the 1.5 T MRI component of the MRL during 
and after irradiation. To our knowledge, this is the first time 
the dose accumulation inside a 3D dosimeter has been 
visualized in real-time during irradiation using the MRL. The 
results of this study warrant further investigations into the 
use of 3D dosimeters for the verification of patient specific 
radiation therapy treatment plans for the MRL. 
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Purpose or Objective: In radiotherapy, the development of 
bidimensional detectors with the suitable dosimetric features 
for pretreatment quality assurance of the new advanced 
treatment techniques is of interest. Diamond is a valid 
candidate as real-time dosimeter since, contrary to silicon, it 
is an almost tissue equivalent material showing in principle 
no energy dependence. Furthermore, it is possible to product 
large-area polycrystalline diamond wafers with suitable 
electronic properties. In this study we describe the 
performance of DIAPIX, a large area dosimeter used for 
pretreatment verification of intensity modulated treatment 
plans. 
 
Material and Methods: The dosimeter is made of two 
detector-grade adjacent 2.5x2.5cm2 polycrystalline Chemical 
Vapour Deposited (pCVD) diamond samples, each equipped 
with a 12x12 matrix of 144 contacts with a pitch of 2mm, 
connected to a custom-made electronic read-out system. 
Tests of the pCVD diamond dosimeter have been performed 
by means of an Elekta Synergy LINAC, with conventional 
photon beams, with clinical IMRT fields, from prostate and 
breast cancer, and with a VMAT lung treatments. The 
dosimeter was placed at the isocenter and sandwiched inside 
a phantom of water equivalent material. First set of 
measurements under a conventional radiotherapy beam 
aimed to verify the correct behavior of the whole matrix 
under a flat field and to obtain a flatness correction factor 
for each pixel were performed. Afterwards dosimetric maps 
were acquired. Since the area of the prototype under study is 
smaller respect to a typical IMRT field, the dosimeter was 
firstly positioned at the isocenter and then shifted in the 
Latero-Lateral direction. QA plans were computed on the 
phantom using the Treatment Planning System (TPS) Monaco 
v3.2., which uses a MonteCarlo algorithm to compute the 
dose distribution, with a dose grid of 2 mm, and Pinnacle 
v9.2 which uses a collapsed cone convolution respectively for 
the VMAT and IMRT plan. 
 
Results: A comparison between the measured maps and the 
ones predicted by the TPS was performed. As an example, in 
fig 1 is reported the map collected of lung VMAT plan and the 
comparison between the measured profiles of some pixels 
and the ones calculated by Monaco TPS. Dose differences 
with TPS are in general within 5%, apart in the penumbra 
region where the dose gradient is high and where the 
distance-to-agreement is within 3mm. 
 
 
Conclusion: Dose profiles compare favorably with TPS both 
for IMRT and VMAT. These results demonstrate that the pCVD 
diamond device is a suitable detector for dosimetric pre-
treatment verification analysis in modulated radiation 
therapy and for conformal beams. This allows for the 
development of a large area monolithic device with high 
spatial resolution. In a next future, three samples will be put 
together in order to realize a matrix with 432 pixels with a 
total area of 7.5x2.5 cm2.  
This work has been supported by the experiments INFN CSN5 
DIAPIX and IRPT/MIUR. 
 
Poster: Physics track: Dose measurement and dose 
calculation  
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Purpose or Objective: The quality of beam base data (BBD) 
is crucial for the accuracy of dose computation, because 
every measurement error translates into a systematic dose 
computation error. Despite elaborate guidelines and 
recommendations, the quality of BBD measurements cannot 
be verified directly. This constitutes a gap in the clinical QA 
chain. We present a Monte-Carlo (MC) based method to 
validate the self-consistency and overall quality of typical 
BBD measurements. 
 
Material and Methods: BBD are naturally not independent; 
therefore, self-consistency is a sensitive indicator. Ideally, a 
full MC simulation, starting with the primary electron beam, 
would allow benchmarking of individual measurements. This 
requires that the electron beam properties are known, which 
can in turn only be determined indirectly from measurements 
of the photon fields, resulting in a circular problem; not to 
mention that full linac simulations with a final uncertainty fit 
for this purpose still require a long time. Thus, we propose: 
for each accelerator type, a number of electron beam tunes 
are simulated with BEAMnrc and the phase spaces recorded. 
The phase spaces are then decomposed into 5 sources and 
each source is described by a parametric model. The model 
parameters are naturally highly correlated and yield a unique 
parameter fingerprint of the beam tune. Given that the 
photon dose distribution of each source is known, the model 
parameters of a BBD set can be derived by a fitting process. 
If a parameter fingerprint of a measurement does not follow 
ESTRO 35  2016                                                                                                                                                  S379 
________________________________________________________________________________ 
the previously established correlation patterns, the 
measurement can be considered problematic, and the most 
probable parameter fingerprint can be determined by mixing 
the base fingerprints. 
 
Results: Parameter fingerprints for the most frequent 
energies of Varian and Elekta linacs were generated and used 
to validate BBD. The method is very sensitive to problems 
with depth-dose curves (DDC), e.g. incorrect placement of 
the sensitive volume of the detector, spectral dependencies 
of the detector for large fields/large depths, partial-volume-, 
cable- and scatter-effects. Due to the virtually absent scatter 
in small fields, MC is the ideal method to augment and 
validate the self-consistency of small field dosimetry. The 
precision of error detection is in the range of 0.1 mm 
detector position shifts and 0.3% dose error, for DDC from 
5x5 mm² to 400x400 mm². Output factor variations can be 
detected with a sensitivity of 0.2%, MLC positioning 
uncertainty with a sensitivity of 0.1 mm. Typical issues with 
detector types and accelerator models can be identified. 
 
Conclusion: Monte-Carlo derived phase space abstractions 
can be used to validate the self-consistency and overall 
quality of base data measurements and thereby fill a gap in 
the quality assurance chain. Base data can be validated with 
an accuracy of 0.3%, being one order of magnitude better 
than potential experimental errors. 
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Purpose or Objective: To evaluate the accuracy of the 
CyberKnife Synchrony Respiratory Tracking System (RTS) and 
to validate a method for pre-treatment patient-specific 
delivery quality assurance (DQA). 
 
Material and Methods: An EasyCube Phantom (Sun Nuclear), 
consisting of RW3 slabs, was mounted on the ExacTrac (ET) 
Gating Phantom (Brainlab), which can move along the 
superior-inferior axis of the patient to simulate a moving 
target. Eight fiducial markers were implanted in the 
EasyCube for the treatment set-up and for the tracking. A 
Gafchromic EBT3 film (Ashland) was positioned between two 
slabs of the EasyCube, while a PinPoint ionization chamber 
(PTW) was placed in an appropriate insert. The EBT3 films 
were calibrated with a 6MV beam (Trilogy, Varian) from 0 to 
15 Gy and analysed with the multichannel film dosimetry 
performed by the FilmQA Pro software (Ashland). Our 
evaluation was performed in two steps: 1) the films were 
irradiated with single fields perpendicular to the EasyCube 
for several collimators (3 fixed collimators: 15, 30, 60mm; 3 
IRIS openings: 20, 30 and 40mm) and in different dynamic 
conditions (e.g. motion amplitude of the ET Phantom from 8 
to 28 mm). The delivered and planned dose distributions 
were compared with the gamma (γ) analysis method. The 
local γ passing rates (GP) were evaluated using 3 acceptance 
criteria, varying the local dose difference (LDD), the 
distance-to-agreement (DTA) and the dose threshold (TH): 
3%/3mm TH=10%, 2%/2mm TH=30% and 3%/1mm 
TH=50%.Dynamic cases were also delivered with purposefully 
simulated errors (RTS switched off or low coverage of the 
respiratory correlation model). 2) The DQA plans of 6 clinical 
patients were delivered in different dynamic conditions, for a 
total of 19 cases. The measured and planned dose 
distributions were evaluated with the same γ-index criteria 
of step 1 and the measured PinPoint doses were compared 
with the planned mean doses in the sensitive volume of the 
chamber. 
 
 
The test was considered passed if the 3 γ analysis criteria 
yielded a GP>90% or at least 2 criteria yielded a GP>90% and 
the PinPoint dose difference (ΔD) was <5.0%. 
 
Results: The γ analysis of the collimators showed the need to 
use more γ-index criteria to detect the simulated errors. 
Only the stricter DTA criterion drastically failed the test, 
with GP<70%. All of the DQA plans passed the tests, both in 
static and dynamic conditions. The mean GP (±σ) were 
95.5±5.2% (3%/3mm), 98.6±1.4% (2%/2mm) and 97.8±2.2% 
(3%/1mm).The mean ΔD was 2.9±1.8%. No significant 
differences were found between the static and the dynamic 
cases. 
 
Conclusion: The presented method confirms the ability of 
the RTS, if used properly, to treat a moving target with great 
precision. Our pre-treatment patient-specific DQA method 
was robust, combining PinPoint dose measurements and an 
evaluation of dose distributions with EBT3 films. However, 
we found the need of a detailed study of each case, 
especially when one acceptance criterion does not satisfy the 
tolerance level. 
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Purpose or Objective: Apply a validated Monte Carlo (MC) 
tool for independent dose calculation in proton PBS to 
‘patient specific’ quality assurance (QA) tasks 
 
Material and Methods: We had developedand validated a MC 
tool for independent dose calculation[1]. In this work weuse 
this code for: 
- Recalculationof a clinically approved plan from the TPS, to 
evaluate the quality of our TPSsemi-analytical dose 
calculation algorithm at the level of the individualpatient 
- Recalculationof a treatment session using the Log File 
coming from the Therapy ControlSystem (TCS), to evaluate 
differences in 3D dose distribution in patientanatomy taking 
into account the characteristics of spots (energy, position, 
MUetc.) as actually delivered by the machine 
- Simulationof a 2D patient specific QA (2DQA). 
This is aretrospective study on 10 patients done to evaluate 
the possibility ofsubstituting our actual 2DQA measurement 
process with a completely automatic andreliable MC based 
workflow. For each 2DQA TPS and MC dose 
distributionsrecalculated in water equivalent material, at 
different depths, were comparedwith measurements 
performed with an array of 1020 ionization chambers 
